Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 6/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18490867 | 0.88 | RAB9A (0.65) | TSHRLMNARAB9APOLBALDH1A1 | |
| SCHEMBL18453105 | 0.85 | NPC1 (0.52) | TSHRLMNARAB9AALDH1A1DRD3 | |
| SCHEMBL4385569 | 0.85 | DRD2 (0.71) | RAB9AALDH1A1DRD3DRD2L3MBTL1 | |
| SCHEMBL17712975 | 0.84 | NPC1 (0.56) | TSHRLMNARAB9AALDH1A1DRD3 | |
| SCHEMBL17712729 | 0.84 | HDAC3 (0.69) | TSHRLMNARAB9APOLBALDH1A1 | |
| SCHEMBL17712754 | 0.84 | DRD3 (0.47) | TSHRLMNARAB9APOLBALDH1A1 | |
| SCHEMBL14401347 | 0.83 | HDAC3 (0.52) | TSHRLMNARAB9AALDH1A1DRD3 | |
| SCHEMBL18556527 | 0.80 | ALDH1A1 (0.68) | TSHRLMNARAB9APOLBALDH1A1 | |
| SCHEMBL15983426 | 0.80 | TSHR (0.66) | TSHRLMNARAB9APOLBALDH1A1 | |
| SCHEMBL18758237 | 0.80 | NPC1 (0.76) | LMNARAB9APOLBALDH1A1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107108597-B | Dopamine D3 receptor antagonist compounds | 英立维尔英国有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| CN-101291669-A | Use of azabicyclo hexane derivatives | GLAXO GROUP LTD (GB) | 2008-10-22 | — | — | CN | disclosed |
| EP-1917013-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| CN-1946714-A | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | CN | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1751163-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005118549-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | TSHR 134/4885LMNA 4735/4885RAB9A 1474/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | TSHR 148/4885LMNA 4686/4885RAB9A 1000/4885 |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | TSHR 546/4885LMNA 3471/4885RAB9A 1802/4885 |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | DRD3, DRD2, SLC6A3 | TSHR 275/4885LMNA 4856/4885RAB9A 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.